{'52WeekChange': -0.10339254,
 'SandP52WeekChange': 0.0644362,
 'address1': '620 Memorial Drive',
 'address2': '2nd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.15,
 'askSize': 800,
 'averageDailyVolume10Day': 132725,
 'averageVolume': 129460,
 'averageVolume10days': 132725,
 'beta': 0.835714,
 'beta3Year': None,
 'bid': 10.55,
 'bidSize': 900,
 'bookValue': 3.307,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 11.58,
 'dayLow': 10.88,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.977,
 'enterpriseToRevenue': 7.851,
 'enterpriseValue': 175987280,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '866 493 4935',
 'fiftyDayAverage': 16.474285,
 'fiftyTwoWeekHigh': 21.92,
 'fiftyTwoWeekLow': 6.95,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14270164,
 'forwardEps': -2.58,
 'forwardPE': -4.3023257,
 'fromCurrency': None,
 'fullTimeEmployees': 93,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.14353,
 'heldPercentInstitutions': 0.82757,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/scholarrock.com',
 'longBusinessSummary': 'Scholar Rock Holding Corporation, a clinical-stage '
                        'biopharmaceutical company, focuses on the discovery '
                        'and development of medicines for the treatment of '
                        'serious diseases in which signaling by protein growth '
                        'factors plays a fundamental role. Its lead antibody '
                        'product candidate is SRK-015, a novel inhibitor of '
                        'the activation of myostatin, which is in Phase II '
                        'clinical trials for the treatment of spinal muscular '
                        'atrophy. The company is also developing SRK-181, '
                        'which is in Phase I clinical trials for the treatment '
                        'of cancers that are resistant to checkpoint inhibitor '
                        'therapies, such as anti-PD-1 or anti-PD-L1. In '
                        'addition, it is developing a pipeline of novel '
                        'product candidates for a range of serious diseases, '
                        'including neuromuscular disorders, cancer, fibrosis, '
                        'and anemia. The company has a collaboration agreement '
                        'with Gilead Sciences, Inc. to discover and develop '
                        'specific inhibitors of transforming growth factor '
                        'beta activation for the treatment of fibrotic '
                        'diseases. Scholar Rock Holding Corporation was '
                        'founded in 2012 and is headquartered in Cambridge, '
                        'Massachusetts.',
 'longName': 'Scholar Rock Holding Corporation',
 'market': 'us_market',
 'marketCap': 331600288,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_548810128',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -57315000,
 'nextFiscalYearEnd': 1640908800,
 'open': 11.58,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 259 3860',
 'previousClose': 11.61,
 'priceHint': 2,
 'priceToBook': 3.3565166,
 'priceToSalesTrailing12Months': 14.793017,
 'profitMargins': -2.55688,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 11.58,
 'regularMarketDayLow': 10.88,
 'regularMarketOpen': 11.58,
 'regularMarketPreviousClose': 11.61,
 'regularMarketPrice': 11.58,
 'regularMarketVolume': 152545,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 29808200,
 'sharesPercentSharesOut': 0.078600004,
 'sharesShort': 2349480,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1878096,
 'shortName': 'Scholar Rock Holding Corporatio',
 'shortPercentOfFloat': 0.1492,
 'shortRatio': 14.3,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SRRK',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.01,
 'twoHundredDayAverage': 15.2633095,
 'volume': 152545,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://scholarrock.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}